This guidance update is purely a mechanical adjustment for deal-related costs. Monitor the Q3 2026 earnings release for operational performance and any further acquisition-related expenses. The Apogee Therapeutics acquisition (announced July 31, 2026) is expected to close in Q3 2026 and may drive additional IPR&D charges.
Price Chart
Executive Summary
AbbVie filed an 8-K updating its full-year 2026 adjusted diluted EPS guidance to $13.76-$13.96, incorporating a $216 million Q3 2026 acquired IPR&D and milestones expense ($0.11/share dilutive). The Q3 2026 adjusted diluted EPS guidance range is $3.73-$3.77. This is a routine guidance adjustment for deal-related costs, not an operational miss.
Key Facts
- Full-year 2026 adjusted diluted EPS guidance lowered to $13.76-$13.96 from $13.87-$14.07, reflecting $0.11/share dilution from Q3 2026 acquired IPR&D and milestones expense of $216 million.
- Q3 2026 adjusted diluted EPS guidance range is $3.73-$3.77, including the $0.11/share impact of acquired IPR&D and milestones.
- The $216 million expense relates to collaborations, licensing agreements, and other asset acquisitions — not operational performance.
- AbbVie does not forecast acquired IPR&D and milestones expense beyond Q3 2026 due to uncertainty of future transactions.
Financial Impact
Full-year adjusted diluted EPS guidance midpoint reduced by $0.11 to $13.86, driven entirely by $216 million in acquired IPR&D and milestones expense.
Risk Factors
- Further acquired IPR&D and milestones expenses beyond Q3 2026 could pressure adjusted EPS.
- Integration costs or delays related to the Apogee Therapeutics acquisition may impact future guidance.
- Operational performance in Q3 2026 remains unreported; preliminary estimates are subject to closing procedures.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000030 |
| Document: abbv-20260930nonxgaapxex991.htm | 0001551152-26-000030 |
| Document: 0001551152-26-000030-index-headers.html | 0001551152-26-000030 |
| Document: 0001551152-26-000030-index.html | 0001551152-26-000030 |
| Document: 0001551152-26-000030.txt | 0001551152-26-000030 |
| 8-K Data (Synthetic) | 0001551152-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | Institutional Cluster | $282.68 | awaiting T+60 | — | $286.74 (+1.44%) |
Oct 15, 2026 12d ago | 8-K | $285.42 | awaiting T+60 | — | $286.74 (+0.46%) |
Oct 5, 2026 22d ago | 8-K | $265.06 | awaiting T+60 | — | $286.74 (+8.18%) |
Sep 28, 2026 4w ago | Court Ruling | $263.29 | awaiting T+60 | — | $286.74 (+8.91%) |
Sep 14, 2026 6w ago | Court Ruling | $261.43 | awaiting T+60 | — | $286.74 (+9.68%) |
Sep 3, 2026 7w ago | 8-K | $260.21 | awaiting T+60 | — | $286.74 (+10.20%) |
Aug 5, 2026 11w ago | 8-K | $243.87 | awaiting T+60 | — | $286.74 (+17.58%) |
Aug 2, 2026 12w ago | Institutional Cluster | $245.10 $286.97 | ▲ +17.08% | ▲ +15.30% | $286.74 (+16.99%) |
Aug 3, 2026 12w ago | Court Ruling | $243.80 | awaiting T+60 | — | $286.74 (+17.61%) |
Jul 31, 2026 12w ago | 8-K | $250.94 $286.74 | ▲ +14.27% | ▲ +11.81% | $286.74 (+14.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers